AU7127600A - Methods and compositions for modulating responsiveness to corticosteroids - Google Patents

Methods and compositions for modulating responsiveness to corticosteroids

Info

Publication number
AU7127600A
AU7127600A AU71276/00A AU7127600A AU7127600A AU 7127600 A AU7127600 A AU 7127600A AU 71276/00 A AU71276/00 A AU 71276/00A AU 7127600 A AU7127600 A AU 7127600A AU 7127600 A AU7127600 A AU 7127600A
Authority
AU
Australia
Prior art keywords
corticosteroids
compositions
methods
modulating responsiveness
responsiveness
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU71276/00A
Other languages
English (en)
Inventor
Subhashis Banerjee
Adam Carter
Tariq Ghayur
Les Sekut
Daniel E. Tracey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF SE
Original Assignee
BASF SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BASF SE filed Critical BASF SE
Publication of AU7127600A publication Critical patent/AU7127600A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU71276/00A 1999-09-17 2000-09-08 Methods and compositions for modulating responsiveness to corticosteroids Abandoned AU7127600A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39855599A 1999-09-17 1999-09-17
US09398555 1999-09-17
PCT/US2000/024725 WO2001019373A2 (fr) 1999-09-17 2000-09-08 Procedes et compositions permettant de moduler la sensibilite aux corticosteroides

Publications (1)

Publication Number Publication Date
AU7127600A true AU7127600A (en) 2001-04-17

Family

ID=23575827

Family Applications (1)

Application Number Title Priority Date Filing Date
AU71276/00A Abandoned AU7127600A (en) 1999-09-17 2000-09-08 Methods and compositions for modulating responsiveness to corticosteroids

Country Status (3)

Country Link
AR (1) AR025669A1 (fr)
AU (1) AU7127600A (fr)
WO (1) WO2001019373A2 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7704944B2 (en) 1997-08-14 2010-04-27 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use for the treatment of sepsis
US7220717B2 (en) 1997-08-14 2007-05-22 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use
IL121860A0 (en) 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
AU7250301A (en) * 2000-06-22 2002-01-02 Willy Ben Moussa Ben Mohammed Use of glucocorticosteroids for producing a medicament to treat oligotrichia
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
US8080247B2 (en) 2000-08-07 2011-12-20 Janssen Biotech, Inc. Anti-IL-12 antibodies
EP1369118A1 (fr) * 2002-06-04 2003-12-10 B.R.A.H.M.S Aktiengesellschaft Procédé et agent pour ls prevention, inhibition et thérapie de sepsie
WO2004093907A2 (fr) * 2003-04-23 2004-11-04 Tomoaki Hoshino Agent therapeutique destine a la dermatite et/ou l'alopecie et/ou les demangeaisons, methode d'evaluation de l'agent therapeutique destine a l'alopecie et/ou les demangeaisons, et nouvel animal transgenique
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
US20070287689A1 (en) * 2004-10-13 2007-12-13 Kyowa Hakko Kogyo Co., Ltd. Therapeutic And/Or Preventive Agents For Chronic Skin Diseases
AU2006270165B2 (en) 2005-07-14 2010-03-11 Neothetics, Inc. Sustained release enhanced lipolytic formulation for regional adipose tissue treatment
JP2009529053A (ja) * 2006-03-07 2009-08-13 コンビナトアールエックス インコーポレーティッド 免疫炎症性障害の処置のための組成物および方法
GB2443287B (en) * 2006-10-17 2009-05-27 Lipothera Inc Methods, compositions and formulations for the treatment of thyroid eye disease
US9132084B2 (en) 2009-05-27 2015-09-15 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
TW201231042A (en) 2010-11-24 2012-08-01 Lithera Inc Selective, lipophilic, and long-acting beta agonist monotherapeutic formulations and methods for the cosmetic treatment of adiposity and contour bulging
WO2015063669A1 (fr) 2013-10-30 2015-05-07 Wockhardt Limited Compositions pharmaceutiques comprenant une combinaison de roflumilast et d'acébrophylline ou de leurs sels pharmaceutiquement acceptables
WO2017172771A2 (fr) 2016-03-29 2017-10-05 Janssen Biotech, Inc. Méthode de traitement du psoriasis par l'augmentation de l'espacement des doses d'anticorps anti-il-12/23
TW201922780A (zh) * 2017-09-25 2019-06-16 美商健生生物科技公司 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
WO2019220412A2 (fr) 2018-05-18 2019-11-21 Janssen Biotech, Inc. Méthode sûre et efficace de traitement du lupus avec un anticorps anti-il12/il23
CA3113837C (fr) 2018-09-24 2022-07-12 Janssen Biotech, Inc. Methode sure et efficace de traitement de la rectocolite hemorragique avec un anticorps anti-il12/il23
BR112021023295A2 (pt) 2019-05-23 2022-02-08 Janssen Biotech Inc Método de tratamento de doença inflamatória intestinal com uma terapia de combinação de anticorpos para il-23 e tnf-alfa

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2588474B1 (fr) * 1985-10-16 1987-11-27 Cird Compositions synergetiques anti-inflammatoires a base d'un corticosteroide et d'un beta agoniste
DK0416950T3 (da) * 1989-09-08 1993-10-11 Glaxo Group Ltd Medikamenter
CA2282845A1 (fr) * 1997-03-18 1998-09-24 Basf Aktiengesellschaft Procedes et compositions permettant de moduler la sensibilite aux corticosteroides
AU755273B2 (en) * 1998-03-16 2002-12-05 Cytovia, Inc. Dipeptide caspase inhibitors and the use thereof

Also Published As

Publication number Publication date
AR025669A1 (es) 2002-12-11
WO2001019373A3 (fr) 2001-10-04
WO2001019373A2 (fr) 2001-03-22

Similar Documents

Publication Publication Date Title
IL131815A0 (en) Methods and compositions for modulating responsiveness to corticosteroids
AU7127600A (en) Methods and compositions for modulating responsiveness to corticosteroids
AU3995799A (en) Methods and compositions for expression of transgenes in plants
AUPQ419099A0 (en) Novel compositions and methods
AU2001239947A1 (en) Methods and compositions for regulating adipocytes
AU3933200A (en) Compositions and methods for controlling pests
AU3671099A (en) Methods and compositions pertaining to pd-loops
AU3387599A (en) Methods and compositions for tissue regeneration
AU7389300A (en) Methods of administration of glycopyrrolate compositions
AU4193700A (en) Antisense oligonucleotide compositions and methods for the modulation of jnk proteins
AU7620200A (en) Compositions and methods relating to the inhibition of casomorphin and gluteomorphin
AU9214398A (en) Compositions and methods for treating water
AU2001293189A1 (en) Compositions and methods for regulating apoptosis
AU7284096A (en) Heterocyclically-substituted 1-indole carboxamides as cyclo-oxygenase-2 inhibitors
AU2051600A (en) Compositions and methods of modulating cholesterol metabolism
AU2349399A (en) R-lansoprazole compositions and methods
AU2001292864A1 (en) Methods and compositions for modulating angiogenesis
AU2001271031A1 (en) Cosmetic compositions for reducing and method of using the same
AU6618900A (en) Compositions useful as desiccants and methods relating thereto
AU4215399A (en) Dermatological compositions and methods
AU2668699A (en) Methods and compositions for modulating leptin activity
AU4981199A (en) Compositions and methods for modulating sexual activity
AU1683801A (en) Methods and compositions for modulating er-stress-induced cholesterol/triglyceride accumulation
EP1231830A4 (fr) Compositions et procedes de modulation de la division cellulaire d'une plante
AU4895297A (en) Methods and compositions for enhancing the expression of genes in plants

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase